[Form 3] ASCENTAGE PHARMA GROUP INTERNATIONAL Initial Statement of Beneficial Ownership
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
ASCENTAGE PHARMA GROUP INTERNATIONAL Chairman and CEO Yang Dajun filed an initial Form 3 showing his equity interests in the company. The filing reports direct ownership of 1,097,994 Ordinary Shares, along with direct holdings of options and restricted stock units tied to additional Ordinary Shares.
The derivative positions include options over 143,463 Ordinary Shares and restricted stock units over another 143,463 Ordinary Shares, vesting in four equal increments on each of 11/26/2026, 2027, 2028 and 2029. The options have an exercise price of $8.14 per share, shown in USD based on the grant-date conversion from HKD.
Entities associated with Yang, including the Dajun Yang Dynasty Trust, his spouse, and an entity controlled by his spouse, hold 22,054,131, 312,534 and 14,089,111 Ordinary Shares, respectively. The filing states that Yang disclaims beneficial ownership of these indirect holdings except to the extent of his pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Yang Dajun
Role
Chairman and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Restricted stock units | -- | -- | -- |
| holding | Restricted stock units | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Options — 143,463 shares (Direct);
Options — 103,364 shares (Indirect, See Footnote (6));
Restricted stock units — 143,463 shares (Direct);
Restricted stock units — 103,364 shares (Indirect, See footnote (6));
Ordinary Shares — 1,097,994 shares (Direct);
Ordinary Shares — 22,054,131 shares (Indirect, See Footnote (1))
Footnotes (1)
- Shares held by Dajun Yang Dynasty Trust, of which the Reporting Person is the investment advisor. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Shares held by Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Shares held by HealthQuest Pharma Limited, an entity controlled by the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. The stock options vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant. Securities held by the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029 and have no expiration date.
FAQ
What does Yang Dajun’s Form 3 for ASCENTAGE PHARMA (AAPG) show?
The Form 3 reports Yang Dajun’s initial ownership in ASCENTAGE PHARMA, including 1,097,994 directly held Ordinary Shares plus options and restricted stock units over additional shares, along with several large indirect holdings through a trust, spouse, and a spouse-controlled entity.
What stock options are reported for Yang Dajun in ASCENTAGE PHARMA (AAPG)?
The filing lists options over 143,463 Ordinary Shares held directly and 103,364 held indirectly. These options have an $8.14 exercise price, vest in four equal annual installments from November 26, 2026 to 2029, and expire on November 26, 2035.
What restricted stock units (RSUs) does Yang Dajun hold in ASCENTAGE PHARMA (AAPG)?
Yang Dajun has RSUs over 143,463 Ordinary Shares directly and 103,364 indirectly. Each RSU converts into one Ordinary Share upon vesting, with vesting in four equal installments on November 26 of 2026, 2027, 2028 and 2029, and no expiration date.
How are Yang Dajun’s indirect ASCENTAGE PHARMA (AAPG) holdings structured?
Indirect holdings are reported through the Dajun Yang Dynasty Trust, his spouse, and HealthQuest Pharma Limited, an entity controlled by his spouse. These entities collectively hold tens of millions of Ordinary Shares, and Yang disclaims beneficial ownership except for any pecuniary interest.
Does Yang Dajun claim full beneficial ownership of all reported ASCENTAGE PHARMA (AAPG) shares?
No. For shares held by the Dajun Yang Dynasty Trust, his spouse, and HealthQuest Pharma Limited, Yang expressly disclaims beneficial ownership except to the extent of his pecuniary interest, and states that their inclusion should not be deemed an admission of beneficial ownership.